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Introduction
Although the presence of lymph-node metastasis is a
negative prognostic factor for breast cancer and other
cancers, it is still not possible to reliably identify, by means
of only lymph node status at primary therapy, those
patients who will relapse with metastatic disease. This
indicates that other ways of metastatic tumor cell spread
also have an important role [1]. Therefore, the availability
of additional factors enabling individual risk assessment is
desirable, to improve the identification of patients at risk
for relapse. Immunocytochemical and molecular assays
now enable the specific detection of metastatic tumor
cells even at the single-cell stage and allow an approach
to the important question of systemic tumor cell
dissemination as one of the first crucial steps in the
metastatic cascade. Several studies in breast cancer have
shown that the presence of disseminated tumor cells
(DTCs) in bone marrow seems to represent an additional
clinical marker that might be useful for clinical decision
making so as to establish risk-adapted adjuvant treatment
strategies. Another important and – in comparison with
other markers – unique application of the detection of
DTCs could be the monitoring of therapeutic efficacy in
the adjuvant setting with no measurable disease.
Detection of micrometastatic tumor cells in
bone marrow
So far, most experience with bone marrow screening for
occult metastatic breast cancer cells has been gained from
immunocytochemical analyses with Ficoll density gradient
centrifugation for tumor cell enrichment. The most recent
studies [2–7] consistently reported that the presence of
DTCs in bone marrow has a strong prognostic impact on
patient survival. This was also confirmed in a pooled
analysis by Braun and colleagues including 4199 patients
with a 10-year follow-up [8]. However, even in these
studies, a diversity of antibodies was used for the
identification of epithelial cells in bone marrow, and the
number of cells analyzed per patient varied or was not
stated, thus introducing substantial variation into the
methodology. To establish a standardized procedure for
bone marrow examination, a prospective two-center study in
primary breast cancer patients was initiated, using a
validated immunoassay. Multivariate regression analysis
verified that the presence of DTCs in bone marrow predicts
poor prognosis independently of the lymph node status [2].
In this context, two more recent reports of the group of
Naume and colleagues are also of considerable
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importance. The first report [6] confirmed the independent
prognostic value of DTC detection in bone marrow in a
cohort of 817 patients. In addition, this study compared the
information derived from the ‘traditional’ enrichment of
mononuclear cells by Ficoll gradient with an immuno-
magnetic enrichment technique that used magnetic
antibodies to deplete white blood cells and was able to
increase the detection rate for DTCs. Interestingly, the higher
rate of detection of positive patients with this technique did
not improve the prognostic value of DTC detection.
In a second report [9], Naume’s group showed that a
morphologic evaluation of the cells detected by positive
staining with an anti-cytokeratin antibody is important in
determining their prognostic impact. In addition, the
authors showed that an increasing number of DTCs in
bone marrow per patient indicates an increasingly poor
prognosis. This again highlights the need for standardized
methodology in DTC detection.
Another important application of DTC detection might be
the monitoring of therapeutic efficacy in the adjuvant
setting. A report by Janni and colleagues suggested that
the presence of DTCs after adjuvant treatment might be
able to identify patients with an increased risk for
recurrence [10]. In a larger study, Naume and colleagues
confirmed this observation [11]; this examination might
therefore be able to identify patients who need additional
adjuvant therapy, for example a prolonged endocrine
treatment that could offer additional benefit for some
patients [12]. However, no study has so far established
the best time point for the re-examination of bone marrow
after primary treatment.
Circulating tumor cells in the peripheral blood
Peripheral blood would be an ideal source for the
detection of DTCs because of ease of sampling. However,
the prognostic significance of circulating tumor cells
(CTCs) is much less clear than for DTCs in bone marrow.
For tumor cells, blood is only a temporary compartment,
and it is not known whether a significant proportion of
CTCs survive and are subsequently capable of forming
detectable metastases. One report by Mehes and
colleagues observed that a large proportion of CTCs in
breast cancer patients are apoptotic [13]. However, it was
shown that the presence of CTCs in breast cancer
patients detected by immunocytochemical or molecular
methods was correlated with stage and course of the
disease [14,15] and there are also more recent reports
showing a prognostic impact of CTCs. Stathopoulou and
colleagues described a negative prognostic impact of
CTCs detected by reverse transcriptase polymerase chain
reaction (PCR) for cytokeratin 19 in the blood of non-
metastatic breast cancer patients before adjuvant therapy
[16], and one report by Weigelt and colleagues, who used
a multimarker PCR assay in metastatatic patients, also
found a negative prognostic impact [17]. These findings
indicate that CTCs have malignant potential.
Using conventional Ficoll gradient centrifugation and
immunocytochemistry, Piegra and colleagues have recently
shown a correlation between the detection of CTCs in the
blood and DTCs in bone marrow of patients with primary
breast cancer, but only the presence of DTCs in bone
marrow provided significant prognostic information [7].
However, the optimal time point for the blood examination
is not clear and, in addition, Ficoll gradient centrifugation of
blood might not provide sufficient enrichment of malignant
cells. An important advance therefore seems to be the
development of new enrichment systems for CTCs
[18,19]. Hayes and colleagues showed in a prospective
study that CTC detection with the use of an automated
enrichment system provided significant prognostic
information in patients with metastatic breast cancer [19].
However, the clinical application for such a detection
system has to be demonstrated in a study that is able to a
show a benefit for patients, for example by changing
therapy regimens in patients with increasing CTC numbers
and thereby improving their outcome. It would also be
important to explore this test system in patients with non-
metastatic breast cancer.
Genetic characterization of disseminated
cancer cells
Recent technical developments permit the examination of
the genome of single disseminated cancer cells. Using a
combination of immunocytochemistry and fluorescence in
situ hybridization, several groups have reported numerical
chromosomal aberrations in cytokeratin-positive cancer
cells in bone marrow and blood, indicating the malignant
origin of these disseminated cells [20–22]. The availability
of new protocols for the amplification of the whole genome
has enabled a more detailed analysis of DTCs. Using single-
cell comparative genomic hybridization, Klein and
colleagues were able to demonstrate that cytokeratin-
positive cells in bone marrow of breast cancer patients
without clinical signs of overt metastases (stage M0) are
genetically heterogeneous [23,24]. Surprisingly, these cells
bore little resemblance to their respective primary tumor
[24]. Besides potential technical problems, a possible
interpretation of this finding is that the disseminated cancer
cells might have separated from their primary tumor at an
early stage and evolved independently, influenced by the
specific selective pressures of the bone marrow
environment. Although this hypothesis adds a new
perspective to the currently debated models of metastasis,
the study by the group of Klein and colleagues [24] did not
address the viability and proliferative potential of the
disseminated cells that were demonstrated in another study
[22]. It is therefore unclear whether the cells analyzed are
capable of developing into metastases and which of the
genomic alterations observed in DTCs are clinically relevant.260
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Conclusions and perspectives
Various immunocytochemical and molecular methods have
been applied to detect occult hematogenous tumor cell
spread in breast cancer patients. International consensus
is now urgently needed on quality-control issues and
criteria for acceptable technical assay performance, to
permit comparisons between different assay platforms. In
addition, marker implementation into current risk
classification systems, such as the tumor–node–
metastasis (TNM) classification system, is needed. The
most recent TNM classification for breast cancer [25] does
not qualify the presence of CTCs in peripheral blood or
DTCs in bone marrow as metastasis, but it optionally
reports the presence of such cells together with their
detection method, e.g. M0(i+) for immunocytochemical
detection or M0(mol+) for detection by molecular methods.
In addition to the detection of DTCs in bone marrow and
CTCs in blood discussed here, the detection of
micrometastases in the lymph nodes as another
independent prognostic indicator is significant and could
have a role in tumor staging.
Beyond adding another prognostic factor in breast cancer,
the potential of occult hematogenous tumor cell spread as
a tool for predicting or monitoring the efficacy of systemic
therapy is of great importance. In contrast to lymph nodes,
which are generally removed at primary surgery, bone
marrow and blood can be obtained repeatedly during
post-operative treatment. The therapeutic efficacy of
adjuvant systemic therapy can currently be assessed only
retrospectively in large-scale clinical trials after an
observation period of at least 5 years. Consequently,
progress with this form of therapy is extremely slow and it
is also not possible to tailor therapy to an individual
patient. The potential of a surrogate marker assay that
permits the immediate assessment of therapy-induced
cytotoxic effects on occult metastatic cells is therefore
evident. Prospective clinical studies are now required, to
evaluate whether the eradication of DTCs in bone marrow
and blood after systemic therapy translates into a longer
disease-free period and overall survival. An additional
important future goal is the possibility of identifying
specific targets for metastatic tumors to improve
chemotherapy regimens.
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